Impaired adiponectin-AMPK signalling in insulin-sensitive tissues of hypertensive rats

Life Sciences

Volumn 83, Issue 15-16, 2008, Pages 540-549

  Rodríguez, Amaia ^a,b   Catalán, Victoria ^a,b   Becerril, Sara ^a,b   Gil, María Jesús ^a,b   Mugueta, Carmen ^a   Gómez Ambrosi, Javier ^a,b   Frühbeck, Gema ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Adiponectin receptors; Hypertension; Insulin resistance; Lipid metabolism

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; CARNITINE PALMITOYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FATTY ACID OXIDATION; GLUCOSE INTOLERANCE; HYPERTENSION; INSULIN RESISTANCE; LIPID STORAGE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ADIPONECTIN; ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; EPIDIDYMIS; FATTY ACIDS; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; LIVER; MALE; MUSCLE CELLS; OXIDATION-REDUCTION; RATS; RATS, INBRED SHR; RATS, WISTAR; RECEPTORS, ADIPONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

RATTUS;

EID: 52149122485     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.07.022     Document Type: Article

References (48)

1. Arendshorst W., Chatziantoniou C., and Daniels F. Role of angiotensin in the renal vasoconstriction observed during the development of genetic hypertension. Kidney International 30 (1990) S92-S96
2. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications 257 1 (1999) 79-83
3. Bandyopadhyay G.K., Yu J.G., Ofrecio J., and Olefsky J.M. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 55 8 (2006) 2277-2285
4. Barnea M., Shamay A., Stark A.H., and Madar Z. A high-fat diet has a tissue-specific effect on adiponectin and related enzyme expression. Obesity 14 12 (2006) 2145-2153
5. Blüher M., Bullen Jr. J.W., Lee J.H., Kralisch S., Fasshauer M., Klöting N., Niebauer J., Schön M.R., Williams C.J., and Mantzoros C.S. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. Journal of Clinical Endocrinology and Metabolism 91 6 (2006) 2310-2316
6. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 (1976) 248-254
7. Bruce C.R., Mertz V.A., Heigenhauser G.J., and Dyck D.J. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes 54 11 (2005) 3154-3160
8. Catalán V., Gómez-Ambrosi J., Rotellar F., Silva C., Gil M.J., Rodríguez A., Cienfuegos J.A., Salvador J., and Frühbeck G. The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus. Clinical Endocrinology 66 4 (2007) 598-601
9. Cesari M., Pessina A.C., Zanchetta M., De Toni R., Avogaro A., Pedon L., Dorigatti F., Maiolino G., and Rossi G.P. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients. Journal of Internal Medicine 260 5 (2006) 474-483
10. Chen M.P., Tsai J.C., Chung F.M., Yang S.S., Hsing L.L., Shin S.J., and Lee Y.J. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 25 4 (2005) 821-826
11. Clasen R., Schupp M., Foryst-Ludwig A., Sprang C., Clemenz M., Krikov M., Thone-Reineke C., Unger T., and Kintscher U. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46 1 (2005) 137-143
12. Cockcroft D., and Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 16 1 (1976) 31-41
13. Eckel R., Grundy S., and Zimmet P. The metabolic syndrome. Lancet 365 9468 (2005) 1415-1428
14. Fruebis J., Tsao T., Javorschi S., Ebbets-Reed D., Erickson M., Yen F., Bihain B., and Lodish H. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. The Proceedings of the National Academy of Sciences of United States of America 98 4 (2001) 2005-2010
15. Frühbeck G., and Salvador J. Role of adipocytokines in metabolism and disease. Nutrition Research 24 (2004) 803-826
16. Fujioka S., Matsuzawa Y., Tokunaga K., Kawamoto T., Kobatake T., Keno Y., Kotani K., Yoshida S., and Tarui S. Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity. International Journal of Obesity 15 12 (1991) 853-859
17. George J., Patal S., Wexler D., Sharabi Y., Peleg E., Kamari Y., Grossman E., Sheps D., Keren G., and Roth A. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92 10 (2006) 1420-1424
18. Hotta K., Funahashi T., Bodkin N., Ortmeyer H., Arita Y., Hansen B., and Matsusawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50 5 (2001) 1126-1133
19. Inukai K., Nakashima Y., Watanabe M., Takata N., Sawa T., Kurihara S., Awata T., and Katayama S. Regulation of adiponectin receptor gene expression in diabetic mice. American Journal of Physiology - Endocrinology and Metabolism 288 5 (2005) E876-E882
20. Iwashima Y., Katsuya T., Ishikawa Y., Ouchi N., Ohishi M., Sugimoto K., Fu Y., Motone M., Yamamoto K., Matsuo A., Ohashi K., Kihara S., Funahashi T., Rakugi H., Matsuzawa Y., and Ogihara T. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43 6 (2004) 1318-1323
21. Kistorp C., Faber J., Galatius S., Gustafsson F., Frystyk J., Flyvbjerg A., and Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112 12 (2005) 1756-1762
22. Kraegen E., Saha A., Preston E., Wilks D., Hoy A., Cooney G., and Ruderman N. Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. American Journal of Physiology - Endocrinology and Metabolism 290 3 (2006) E471-E479
23. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., Arita Y., Okamoto Y., Shimomura I., Hiraoka H., Nakamura T., Funahashi T., and Matsuzawa Y. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thrombosis, and Vascular Biology 23 1 (2003) 85-89
24. Labarthe F., Khairallah M., Bouchard B., Stanley W.C., and Des Rosiers C. Fatty acid oxidation and its impact on response of spontaneously hypertensive rat hearts to an adrenergic stress: benefits of a medium-chain fatty acid. American Journal of Physiology - Heart and Circulatory Physiology 288 3 (2005) H1425-1436
25. Lessard S., Chen Z., Watt M., Hashem M., Reid J., Febbraio M., Kemp B., and Hawley J. Chronic rosiglitazone treatment restores AMPKalpha2 activity in insulin-resistant rat skeletal muscle. American Journal of Physiology - Endocrinology and Metabolism 290 2 (2006) E251-E257
26. Long Y., and Zierath J. AMP-activated protein kinase signaling in metabolic regulation. The Journal of Clinical Investigation 116 7 (2006) 1776-1783
27. Mallamaci F., Zoccali C., Cuzzola F., Tripepi G., Cutrupi S., Parlongo S., Tanaka S., Ouchi N., Kihara S., Funahashi T., and Matsusawa Y. Adiponectin in essential hypertension. Journal of Nephrology 15 5 (2002) 507-511
28. McAinch A., Steinberg G., Mollica J., O'Brien P., Dixon J., Macaulay S., Kemp B., and Cameron-Smith D. Differential regulation of adiponectin receptor gene expression by adiponectin and leptin in myotubes derived from obese and diabetic individuals. Obesity 14 11 (2006) 1898-1904
29. Miao B., Zondlo S., Gibbs S., Cromley D., Hosagrahara V., Kirchgessner T., Billheimer J., and Mukherjee R. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. Journal of Lipid Research 45 8 (2004) 1410-1417
30. Mullen K., Smith A., Junkin K., and Dyck D. Globular adiponectin resistance develops independently of impaired insulin-stimulated glucose transport in soleus muscle from high-fat fed rats. American Journal of Physiology - Endocrinology and Metabolism 293 1 (2007) E83-E90
31. PE Applied Biosystems. Relative quantitation of Gene Expression (1997), The PerkinElmer Corporation, Foster City, CA User bulletin #2
32. Pravenec M., Zidek V., Landa V., Simakova M., Mlejnek P., Kazdova L., Bila V., Krenova D., and Kren V. Genetic analysis of "metabolic syndrome" in the spontaneously hypertensive rat. Physiological Research 53 1 (2004) S15-S22
33. Rodríguez A., Frühbeck G., Gómez-Ambrosi J., Catalán V., Sáinz N., Díez J., Zalba G., and Fortuño A. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. Journal of Hypertension 24 8 (2006) 1589-1597
34. Rodríguez A., Catalán V., Gómez-Ambrosi J., and Frühbeck G. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome?. Current Pharmaceutical Design 13 21 (2007) 2169-2175
35. Saraheimo M., Forsblom C., Fagerudd J., Teppo A., Pettersson-Fernholm K., Frystyk J., Flyvbjerg A., and Groop P. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 28 6 (2005) 1410-1414
36. Savage D., Choi C., Samuel V., Liu Z., Zhang D., Wang A., Zhang X., Cline G., Yu X., Geisler J., Bhanot S., Monia B., and Shulman G. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. The Journal of Clinical Investigation 116 3 (2006) 817-824
37. Shimabukuro M., Higa N., Asahi T., Oshiro Y., Takasu N., Tagawa T., Ueda S., Shimomura I., Funahashi T., and Matsuzawa Y. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. Journal of clinical endocrinology and metabolism 88 7 (2003) 3236-3240
38. Staiger H., Kaltenbach S., Staiger K., Stefan N., Fritsche A., Guirguis A., Peterfi C., Weisser M., Machicao F., Stumvoll M., and Haring H. Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes 53 9 (2004) 2195-2201
39. Stumvoll M., and Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51 8 (2002) 2341-2347
40. Tsuchida A., Yamauchi T., Ito Y., Hada Y., Maki T., Takekawa S., Kamon J., Kobayashi M., Suzuki R., Hara K., Kubota N., Terauchi Y., Froguel P., Nakae J., Kasuga M., Accili D., Tobe K., Ueki K., Nagai R., and Kadowaki T. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. Journal of Biological Chemistry 279 29 (2004) 30817-30822
41. Vonend O., Okonek A., Stegbauer J., Habbel S., Quack I., and Rump L. Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneously hypertensive rats. Cardiovascular Research 66 2 (2005) 345-352
42. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., and Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 7 8 (2001) 941-946
43. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Wak H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B., and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 8 11 (2002) 1288-1295
44. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., and Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 6941 (2003) 762-769
45. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., Okada-Iwabu M., Kawamoto S., Kubota N., Kubota T., Ito Y., Kamon J., Tsuchida A., Kumagai K., Kozono H., Hada Y., Ogata H., Tokuyama K., Tsunoda M., Ide T., Murakami K., Awazawa M., Takamoto I., Froguel P., Hara K., Tobe K., Nagai R., Ueki K., and Kadowaki T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nature Medicine 13 3 (2007) 332-339
46. Yuan G., Deng J., Wang T., Zhao C., Xu X., Wang P., Voltz J., Edin M., Xiao X., Chao L., Chao J., Zhang X., Zeldin D., and Wang D. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology 148 5 (2007) 2016-2026
47. Zhang Y., Matheny M., Zolotukhin S., Tumer N., and Scarpace P. Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of b3-adrenergic agonists, retinoic acid, leptin and fasting. Biochimica et Biophysica Acta 1584 2-3 (2002) 115-122
48. Zoccali C., Mallamaci F., Tripepi G., Benedetto F., Cutrupi S., Parlongo S., Malatino L., Bonanno G., Seminara G., Rapisarda F., Fatuzzo P., Buemi M., Nicocia G., Tanaka S., Ouchi N., Kihara S., Funahashi T., and Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. Journal of the American Society of Nephrology 13 1 (2002) 134-141